Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced topline results from its Phase 3 registrational clinical trial (the RECONNECT Study) of ...

Harmony Biosciences Holdings (HRMY) is in the spotlight after announcing that its Phase 3 RECONNECT study for ZYN002 in Fragile X syndrome did not meet its main goal, citing higher than expected ...

Shares of Harmony Biosciences plunged Wednesday as Fragile X syndrome continued to be "undruggable" for the biotech company.

Harmony Biosciences said on Wednesday its experimental drug for a rare genetic disorder failed to meet the main goal in a late-stage trial, sending its shares down more than 8%.

In a recent strategic move, Servier agreed to acquire Kaerus Bioscience’s potential Fragile X syndrome (FXS) treatment, KER-0193. "EC approves Servier’s Voranigo to treat IDH-mutant glioma " was ...

Actinogen Medical ( ($AU:ACW) ) has shared an announcement. Actinogen Medical has received a $5.5 million R&D tax incentive rebate from the ...

Hyderabad: In the rapidly evolving world of reproductive medicine, ovarian tissue freezing is emerging as a groundbreaking ...

From diagnosis to the brutal treatment process, here's what veterinary professionals wish every dog owner understood about ...

ACADIA Pharmaceuticals Inc. remains solid with Nuplazid and Daybue cash flows and valuation. Click here to read why ACAD ...

Tragic RSV vaccine trials in the 1960s set the field back for decades. Here’s how scientists finally made breakthroughs in RSV immunization ...